Boston Keratoprosthesis type 1 (KPro) without contact lens wearing in end-stage corneal disease: The APEC experience

Abstract

Purpose

To report the visual outcomes and survival analysis of keratoprosthesis without contact lens wearing in a tertiary eye care hospital in Mexico City, Asociación Para Evitar La Ceguera (APEC, Coyoacán, México).

Design

Retrospective cohort with survival analysis

Participants

Twenty-three eyes (22 patients) received KPro type 1 between 2015 and 2020 with a follow-up time of three years.

Methods

We included analyzed data about past medical history, preoperative diagnosis, best-spectacle visual acuity (BSCVA), postoperative complications and retention rate. Univariate, bivariate and survival analysis were performed and reported.

Results

The mean age was 58 ± 13.5 years (SD). 60.86% were male patients (14 eyes). Twelve-eyes (52%) achieved a BSCVA of 20/200 or better in the first and second year of follow-up. At 3 years, only 35% achieved 20/200 or better (BSCVA). Retention rate of Boston type 1 KPro was 87% (20 eyes) at 3 years follow-up. The most common complication was retroprosthetic membrane (RPM) which occurred in 9 eyes (39.1%), followed by corneal melting in 7 eyes (30.4%).

Conclusions

We report the results of a retrospective cohort of twenty-three eyes (22 patients) who were implanted with a Boston type 1 KPro without contact lens wearing to treat corneal blindness. BSCVA improved significantly in most patients achieving 20/200 or better at the 2-year follow-up. Retention rate was 87%, with the presence of RPM as the most common complication.

Keywords

Survival corneal blindness Boston KPro contact lens extrusion RPM melting

Get full access to this article

View all access options for this article.

References

Tan

Dart

Holland

, et al. Corneal transplantation. Lancet 2012; 379: 1749–1761.

Maguire

Stark

Gottsch

, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative corneal transplantation studies research group. Ophthalmology 1994; 101: 1536–1547.

Hill

. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 1994; 101: 128–133.

Tourkmani

Sánchez-Huerta

D- Wit

, et al. Weighing of risk factors for penetrating keratoplasty graft failure: application of risk score system. Int J Ophthalmol 2017; 10: 372–377.

Aldave

Sangwan

Basu

, et al. International results with the Boston type I keratoprosthesis. Ophthalmology 2012; 119: 1530–1538.

Ahmad

Mathews

Lindsley

, et al. Boston Type 1 keratoprosthesis versus repeat donor keratoplasty for corneal graft failure: a systematic review and meta-analysis. Ophthalmology 2016; 123: 165–177.

Gibbons

Leung

Haddock

, et al. Long-term outcomes of the aphakic snap-on Boston type I keratoprosthesis at the bascom palmer eye institute. Clinical Ophthalmology 2018; 12: 331–337.

Wagoner

Welder

Goins

, et al. Microbial keratitis and endophthalmitis after the Boston type 1 keratoprosthesis. Cornea 2016; 35: 486–493.

Chan

LoVerde

Qiang

, et al. Incidence, risk factors, and surgical management of Boston type 1 keratoprothesis corneal melts, leaks, and extrusions. Cornea 2016; 35: 1049–1056.

10.

Goldman

Hubschman

Aldave

. Postoperative posterior segment complications in eyes treated with the Boston type I keratoprosthesis. Retina 2013; 33: 532–541.

11.

Netland

Terada

Dohlman

. Glaucoma associated with keratoprosthesis. Ophthalmology 1998; 105: 751–757.

12.

Basu

Serna-Ojeda

Senthil

, et al. The aurolab keratoprosthesis (KPro) versus the Boston type I kpro: 5-year clinical outcomes in 134 cases of bilateral corneal blindness. Am J Ophthalmol 2019; Sept 205: 175–183.

13.

Shanbhag

Senthil

Mohamed

, et al. Outcomes of the Boston type 1 and the Aurolab keratoprosthesis in eyes with limbal stem cell deficiency. Br J Ophthalmol 2021; 105: 473–478.

14.

Dohlman

Dudenhoefer

Khan

, et al. Protection of the ocular surface after keratoprosthesis surgery: the role of soft contact lenses. CLAO J 2002; 28: 72–74.

15.

Thomas

Shorter

Joslin

, et al. Contact lens use in patients with Boston keratoprosthesis type 1: fitting, management and complications. Eye Contact Lens 2015; 41: 334–340.

16.

Keratoprosthesis Patient Management. Mass Eye an Ear. 2021, June 28th. https://www.masseyeandear.org/medical-professionals/keratoprosthesis.

17.

Thompson

Jr Price

Bowers

, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003; 110: 1396–1402.

18.

Graney

Dohlman

. Repeat penetrating keratoplasty versus the Boston keratoprosthesis in graft failure. Int Ophthalmol Clin 2005; 45: 49–59.

19.

Bersudsky

Blum-Hareuveni

Rehany

, et al. The profile of repeated corneal transplantation. Ophthalmology 2001; 108: 461–469.

20.

Aldave

Sangwan

Basu

, et al. International results with the Boston type I keratoprosthesis. Ophthalmology 2012; 119: 1530–1538.

21.

Colby

Koo

. Expanding indications for the Boston keratoprosthesis. Current Opin Ophthalmol 2011; 22: 267–273.

22.

Khan

Harissi-Dagher

Khan

, et al. Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin. 2007; 47: 61–71.

23.

Traish

Chodosh

. Expanding application of the Boston type I keratoprosthesis due to advances in design and improved post-operative therapeutic strategies. Semin Ophthalmol 2010; 25: 239–243.

24.

Alexander

Basak

Padilla

, et al. International outcomes of the Boston type I keratoprosthesis in Stevens-Johnson syndrome. Cornea 2015; 34: 1387–1394.

25.

Akpek

Harissi-Dagher

Petrarca

, et al. Outcomes of Boston keratoprosthesis in aniridia: a retrospective multicenter study. Am J Ophthalmol 2007; 144: 227–231.

26.

Aravena

Bozkurt

, et al. Long-Term outcomes of the Boston type I keratoprosthesis in the management of corneal limbal stem cell deficiency. Cornea 2016; 35: 1156–1164.

27.

Bradley

Hernandez

Schwab

, et al. Boston Type 1 keratoprosthesis: the University of California Davis experience. Cornea 2009; 28: 321–327.

28.

Bouhout

Robert

Deli

, et al. Corneal melt after Boston keratoprosthesis: clinical presentation, management, outcomes and risk factor analysis. Ocul Immunol Inflamm 2018; 26: 693–699.

29.

Behlau

Martin

, et al. Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention. Acta Ophthalmol 2014; 92: e546–e555.

30.

Driver

Aravena

Duong

, et al. Outcomes of the Boston type I keratoprosthesis as the primary penetrating corneal procedure. Cornea 2018; 37: 1400–1407.

31.

Schein

Glynn

Poggio

, et al. The relative risk of ulcerative keratitis among users of daily- wear and extended-wear soft contact lenses. N Engl J Med 1989; 321: 773–778.

32.

Liu

Harissi-Dagher

. Comparison of outcomes in patients with and without soft contact lens wear following Boston keratoprosthesis type 1. Can J Ophthalmol 2022; 57: 154–160.

33.

Belin

Güell

Grabner

. Suggested guidelines for reporting keratoprosthesis results: consensus opinion of the Cornea society, Asia Cornea society, EuCornea, PanCornea, and the KPRO study group. Cornea 2016; 35: 143–144.